NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 89 filers reported holding NOVOCURE LTD in Q2 2017. The put-call ratio across all filers is 0.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,051,410 | -62.9% | 127,025 | -4.6% | 0.00% | -66.7% |
Q2 2023 | $5,524,355 | +77905.6% | 133,117 | +13.0% | 0.01% | -33.3% |
Q1 2023 | $7,082 | -8.3% | 117,764 | +11.8% | 0.01% | -10.0% |
Q4 2022 | $7,725 | -99.9% | 105,318 | +2.3% | 0.01% | -16.7% |
Q3 2022 | $7,820,000 | +15.8% | 102,925 | +5.9% | 0.01% | +20.0% |
Q2 2022 | $6,755,000 | -7.0% | 97,190 | +10.8% | 0.01% | +11.1% |
Q1 2022 | $7,267,000 | -1.2% | 87,709 | -10.5% | 0.01% | 0.0% |
Q4 2021 | $7,355,000 | -32.7% | 97,963 | +4.1% | 0.01% | -40.0% |
Q3 2021 | $10,930,000 | -47.9% | 94,086 | -0.6% | 0.02% | -46.4% |
Q2 2021 | $20,998,000 | +61.3% | 94,663 | -3.9% | 0.03% | +55.6% |
Q1 2021 | $13,016,000 | -28.0% | 98,474 | -5.8% | 0.02% | -28.0% |
Q4 2020 | $18,080,000 | +53.5% | 104,484 | -1.3% | 0.02% | +38.9% |
Q3 2020 | $11,778,000 | +77.0% | 105,815 | -5.7% | 0.02% | +63.6% |
Q2 2020 | $6,655,000 | -18.6% | 112,225 | -7.6% | 0.01% | -35.3% |
Q1 2020 | $8,175,000 | -20.1% | 121,395 | +0.0% | 0.02% | 0.0% |
Q4 2019 | $10,229,000 | +19.5% | 121,387 | +6.0% | 0.02% | +6.2% |
Q3 2019 | $8,561,000 | +18.0% | 114,484 | -0.2% | 0.02% | +14.3% |
Q2 2019 | $7,255,000 | +54.2% | 114,747 | +17.5% | 0.01% | +55.6% |
Q1 2019 | $4,706,000 | +47.1% | 97,690 | +2.3% | 0.01% | +28.6% |
Q4 2018 | $3,199,000 | -7.2% | 95,535 | +45.1% | 0.01% | 0.0% |
Q3 2018 | $3,449,000 | +59.3% | 65,820 | -4.8% | 0.01% | +75.0% |
Q2 2018 | $2,165,000 | +82.2% | 69,161 | +26.9% | 0.00% | +100.0% |
Q1 2018 | $1,188,000 | +6.3% | 54,510 | -1.5% | 0.00% | 0.0% |
Q4 2017 | $1,118,000 | -14.2% | 55,340 | -15.7% | 0.00% | -33.3% |
Q3 2017 | $1,303,000 | +15.7% | 65,659 | +0.9% | 0.00% | 0.0% |
Q2 2017 | $1,126,000 | +157.1% | 65,094 | +20.5% | 0.00% | +200.0% |
Q1 2017 | $438,000 | +7.1% | 54,038 | +3.8% | 0.00% | 0.0% |
Q4 2016 | $409,000 | +1.7% | 52,039 | +10.5% | 0.00% | 0.0% |
Q3 2016 | $402,000 | -13.0% | 47,079 | +19.0% | 0.00% | 0.0% |
Q2 2016 | $462,000 | – | 39,571 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |